Compare BIOX & ATYR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BIOX | ATYR |
|---|---|---|
| Founded | 2001 | 2005 |
| Country | | |
| Employees | N/A | N/A |
| Industry | Agricultural Chemicals | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 61.5M | 69.2M |
| IPO Year | N/A | N/A |
| Metric | BIOX | ATYR |
|---|---|---|
| Price | $0.59 | $0.98 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 3 | 8 |
| Target Price | ★ $4.33 | $4.20 |
| AVG Volume (30 Days) | 883.2K | ★ 2.6M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $37.82 | $18,728.88 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.53 | $0.64 |
| 52 Week High | $5.40 | $7.29 |
| Indicator | BIOX | ATYR |
|---|---|---|
| Relative Strength Index (RSI) | 26.93 | 64.06 |
| Support Level | $0.56 | $0.82 |
| Resistance Level | $0.63 | $0.94 |
| Average True Range (ATR) | 0.11 | 0.10 |
| MACD | -0.00 | 0.01 |
| Stochastic Oscillator | 9.19 | 84.89 |
Bioceres Crop Solutions Corp is a fully integrated provider of crop productivity solutions, including seeds, seed traits, seed treatments, biologicals, high-value adjuvants, and fertilizers. The company has developed a multi-discipline and multi-product platform capable of providing solutions throughout the entire crop cycle, from pre-planting to transportation and storage. Some of the products offered by the company include fertilizers, inoculants, adjuvants, crop protection solutions, and seeds among others. Its operating segments are crop protection, which derives key revenue, seed and integrated products, and crop nutrition. Geographically, the majority of the company's revenue is generated from Argentina and the rest from Brazil, North America, Latin America, and other regions.
aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can cause to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.